rsfern

30 ms·

361.
by rsfern 5y ago
I’m not sure about in the UK, but when I had prints taken in the US recently for a background check (my kid is in a coop preschool) they scanned the whole length of my fingers, so maybe they had partial data to match against?
362.
by rsfern 5y ago
Main result from the study being discussed: omicron specific boosters perform the same as original strain boosters (in a macaque challenge trial against omicron variant)
363.
Omicron Boosters and Original Antigenic Sin(science.org)
3 points by rsfern 5y ago|1 comments
364.
by rsfern 5y ago
The JHU site that’s linked is reporting case fatality rates, not infection fatality rates It’s also not estimating case under-reporting like CDC is I think jumping straight to misinformation is a bit strong here, but it’s important to make
365.
by rsfern 5y ago
Isn’t the clotting thing specific to the AZ? I thought that was attributed to the adenovirus vector and not the SARS-CoV-2 spike
366.
by rsfern 5y ago
Yes, based on your personal risk. The vaccine substantially decreases your risk of severe disease from SARS-CoV-2 infection, even if you think that is a low baseline risk. As a young person this comes with a slightly elevated risk of myocar
367.
by rsfern 5y ago
This should be part of our discourse going forward about transparency in clinical trials, but you do not need to rely on this data to make a rational decision to take the vaccine. There is loads of evidence from many different countries now
368.
by rsfern 5y ago
It was posted less than two months ago, that’s a pretty normal time frame for a paper to stay in review depending on the field and journal. Often there are two rounds of review even if the reviews only call for minor revisions
369.
by rsfern 5y ago
That paper was interesting and the bit about clinical trials is important, but they don’t really offer much evidence that there are substantial concentrations of free floating spike proteins in the blood following vaccination, or that this
370.
by rsfern 5y ago
It seems like he was one of the people advocating using CUDA for deep learning before Krizhevsky’s big breakthrough in 2012. Not a primary source: https://medium.com/analytics-vidhya/gpu-for-deep-learning-7f... Alex Kr
371.
by rsfern 5y ago
If you’re not familiar with Matt Might, look into his work on the rare genetic disease that his son has. His story is really quite inspiring, and maybe there will be a strategy that you can apply. Here’s a good post, he’s a prolific blogger
372.
by rsfern 5y ago
I agree with that, it’s the same for conventional TV advertising: pick a channel, pick a time slot, target your demographic I think it’s different from modern web advertising that targets specific adds to specific individuals based on detai
373.
by rsfern 5y ago
To be fair it’s hard to hypertarget newspaper ads. Historically, same for tv, though that’s not necessarily a limitation these days
374.
by rsfern 5y ago
DEI - the post is talking about the diversity, equity, and inclusion statement. Most departments (including at MIT) seem to be asking for one along with research and teaching statements these days, it’s not just the UC system. Calling it a
375.
by rsfern 5y ago
Arxiv.org has been online for 30 years. Is there a specific reason you think they (or the other preprint servers) might grow less open in ten more years? They have a Covid research banner on the front page now, but it’s a reasonable blanket
376.
by rsfern 5y ago
I read a bunch of the early Omicron research, and your assertion is kind of misleading. Sure, the antibody reactivity tests are first because those tests are fast. But a ton of the subsequent research focused on observational studies to qua
377.
by rsfern 5y ago
You can disable formatting for specific lines or blocks with `# fmt: off` https://black.readthedocs.io/en/stable/the_black_code_style/...
378.
by rsfern 5y ago
I used to live two blocks from this bridge. At evening rush hour it’s bumper to bumper traffic Not as bad as like the fort Pitt bridge collapsing or something, but still a big deal
379.
by rsfern 5y ago
This is really cool, but I don’t think it’s an atomistic simulation so I’m not sure where the title is coming from. It seems to be some kind of a (truly impressive) kinetic model The paper in Cell is open access https://doi.org&#
380.
by rsfern 5y ago
The Covid therapeutic and prophylactic literature has been chock full of crap studies, so you really have to be careful taking meta analysis at face value. Some interesting discussion on this, which includes the prophylactic literature: ht
381.
by rsfern 5y ago
You’re describing use as an antiviral, comparable to paxlovid. I don’t think that is the proposed mechanism for this prophylactic ivermectin treatment. If you have a reference you could share, that would be helpful. > Ivermectin does in
382.
by rsfern 5y ago
The clinical trials were placebo controlled, see the sibling comment for a reference to the results, or look up the protocols on clinicaltrials.gov
383.
by rsfern 5y ago
It’s most likely too late for PCR confirmation with these samples, there would need to be actual viral proteins in the blood sample, so an active or very recent infection at the time of the blood draw
384.
by rsfern 5y ago
To add to the other replies, most journals allow you to post a preprint to arxiv or your personal site as long as you don’t use their final layout, typesetting, and branding
385.
by rsfern 5y ago
Hamming specifically defines important as both high impact and high tractability in this essay, so I generally think he would have agreed with you
386.
by rsfern 5y ago
I guess, but it’s a heterogeneous dataset. They even discuss in this manuscript differences between how CA reports stuff compared with NY. (This is kind of a separate issue where CDC could have lead on data standardization, but not everyone
387.
by rsfern 5y ago
They also found that pre-delta (when a lot of the US was getting their primary series) vaccine immunity was more protective against hospitalization with alpha or whatever it was at the time in the US I’m not sure if there is a good study t
388.
by rsfern 5y ago
I don’t think it’s cherry picking so much as maybe working with the limitations of merging 50 datasets vs 2? They at least acknowledge the dataset bias in the discussion section, and they cite a couple similar findings from other countries,
389.
by rsfern 5y ago
Is there solid data supporting that? You seem confident, but I don’t think I’ve come across any omicron-specific data for under 18s at all
390.
by rsfern 5y ago
Those countries generally still offer pfizer for that age group, which has lower myocarditis risk than moderna (presumably because of the dose mostly). I think a lot of European countries also still use astra zeneca, not sure about J&J

More ›